Role of Dermatologists in Treating Melanoma

Authors:
Allan C. HalpernFrom Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

Search for other papers by Allan C. Halpern in
Current site
Google Scholar
PubMed
Close
 MD
and
Sanjay K. MandalFrom Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York.

Search for other papers by Sanjay K. Mandal in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Melanoma is a major focus of dermatology training and practice, with dermatologists playing a central role in managing melanoma through primary prevention, secondary prevention, diagnosis, and treatment of thinner tumors. Dermatologists have led public health efforts to raise melanoma awareness, promulgate the early warning signs of melanoma, and promote melanoma prevention through sun protection. Dermatologists have unique expertise in melanoma risk assessment and the clinical diagnosis of melanoma through visual inspection and the use of diagnostic aids, including dermoscopy and photographically assisted follow-up. Increasing incidence of melanoma, earlier melanoma detection, narrower excision margins, and improved surgical training in dermatology have recently combined to enhance the role of dermatologists in melanoma care. For patients with thin primary melanomas, dermatologists are increasingly assuming complete care, including wide local excision and long-term surveillance for both disease recurrence and detection of new primary melanoma. Conversely, the advent of sentinel lymph node biopsy and adjuvant therapy has made melanoma management more complex and has intensified the need for a multidisciplinary approach to the disease. In this context, dermatologists contribute significantly to the formation, administration, and implementation of multidisciplinary melanoma programs.

Correspondence: Allan C. Halpern, MD, Chief, Dermatology Service, Memorial Sloan-Kettering Cancer Center, 160 East 53rd Street, New York, NY 10022. E-mail: halperna@mskcc.org
  • Collapse
  • Expand
  • 1.

    Jemal A, Murray T, Ward E et al.. Cancer statistics, 2005. CA Cancer J Clin 2005;55:1030.

  • 2.

    de Vries E, Coebergh JW. Melanoma incidence has risen in Europe. BMJ 2005;331:698.

  • 3.

    Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 2005;331:481.

  • 4.

    de Vries E, Schouten LJ, Visser O et al.. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? Eur J Cancer 2003;39:14391446.

    • Search Google Scholar
    • Export Citation
  • 5.

    Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687701.

  • 6.

    Roberts DL, Anstey AV, Barlow RJ et al.. UK guidelines for the management of cutaneous melanoma. Br J Dermatol 2002;146:717.

  • 7.

    Carli P, De Giorgi V, Nardini P et al.. Melanoma detection rate and concordance between self-skin examination and clinical evaluation in patients attending a pigmented lesion clinic in Italy. Br J Dermatol 2002;146:261266.

    • Search Google Scholar
    • Export Citation
  • 8.

    Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 2005;153:11371141.

    • Search Google Scholar
    • Export Citation
  • 9.

    Moretti S, Carli P, Biggeri A et al.. Cohort study of metastatic melanoma patients in the Dermatology Institute of Florence 1990/1997. J Eur Acad Dermatol Venereol 2001;15:3033.

    • Search Google Scholar
    • Export Citation
  • 10.

    Salopek TG, Slade JM, Marghoob AA et al.. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma. J Am Acad Dermatol 1995;33:451461.

    • Search Google Scholar
    • Export Citation
  • 11.

    Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001;63:818.

  • 12.

    Tucker MA, Goldstein AM. Melanoma etiology: where are we? Oncogene 2003;22:30423052.

  • 13.

    Whiteman DC, Watt P, Purdie DM et al.. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:806812.

    • Search Google Scholar
    • Export Citation
  • 14.

    Rivers JK. Is there more than one road to melanoma? Lancet 2004;363:728.

  • 15.

    Berking C. The role of ultraviolet irradiation in malignant melanoma [in German]. Hautarzt 2005;56:687696.

  • 16.

    Pho L, Grossman D, Leachman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. Curr Opin Oncol 2006;18:173179.

    • Search Google Scholar
    • Export Citation
  • 17.

    Kefford RF, Mann GJ. Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 2003;15:157161.

  • 18.

    Uribe P, Andrade L, Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol 2006;126:161166.

    • Search Google Scholar
    • Export Citation
  • 19.

    Yang G, Rajadurai A, Tsao H. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 2005;125:12421251.

  • 20.

    Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 2005;1059:1625.

    • Search Google Scholar
    • Export Citation
  • 21.

    Bliss JM, Ford D, Swerdlow AJ et al.. Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer 1995;62:367376.

    • Search Google Scholar
    • Export Citation
  • 22.

    Marrett LD, King WD, Walter SD, From L. Use of host factors to identify people at high risk for cutaneous malignant melanoma. CMAJ 1992;147:445453.

    • Search Google Scholar
    • Export Citation
  • 23.

    Tucker MA, Halpern A, Holly EA et al.. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277:14391444.

    • Search Google Scholar
    • Export Citation
  • 24.

    Geller AC, Zhang Z, Sober AJ et al.. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999. J Am Acad Dermatol 2003;48:3441.

    • Search Google Scholar
    • Export Citation
  • 25.

    Koh HK, Norton LA, Geller AC et al.. Evaluation of the American Academy of Dermatology's National Skin Cancer Early Detection and Screening Program. J Am Acad Dermatol 1996;34:971978.

    • Search Google Scholar
    • Export Citation
  • 26.

    Aitken JF, Janda M, Elwood M et al.. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol 2006;54:105114.

    • Search Google Scholar
    • Export Citation
  • 27.

    Geller AC, Miller DR, Annas GD et al.. Melanoma incidence and mortality among US whites, 1969–1999. JAMA 2002;288:17191720.

  • 28.

    Geller AC, Sober AJ, Zhang Z et al.. Strategies for improving melanoma education and screening for men age > or = 50 years: findings from the American Academy of Dermatological National Skin Cancer Sreening Program. Cancer 2002;95:15541561.

    • Search Google Scholar
    • Export Citation
  • 29.

    Carli P, De Giorgi V, Palli D et al.. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003;139:607612.

    • Search Google Scholar
    • Export Citation
  • 30.

    Brady MS, Oliveria SA, Christos PJ et al.. Patterns of detection in patients with cutaneous melanoma. Cancer 2000;89:342347.

  • 31.

    Oliveria SA, Dusza SW, Phelan DL et al.. Patient adherence to skin self-examination. Effect of nurse intervention with photographs. Am J Prev Med 2004;26:152155.

    • Search Google Scholar
    • Export Citation
  • 32.

    Epstein DS, Lange JR, Gruber SB et al.. Is physician detection associated with thinner melanomas? JAMA 1999;281:640643.

  • 33.

    Marghoob AA, Slade J, Kopf AW et al.. Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: a case-control study. Br J Dermatol 1996;135:704711.

    • Search Google Scholar
    • Export Citation
  • 34.

    Curley RK, Cook MG, Fallowfield ME, Marsden RA. Accuracy in clinically evaluating pigmented lesions. BMJ 1989;299:1618.

  • 35.

    Wolf IH, Smolle J, Soyer HP, Kerl H. Sensitivity in the clinical diagnosis of malignant melanoma. Melanoma Res 1998;8:425429.

  • 36.

    Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol 2002;3:159165.

  • 37.

    Argenyi ZB. Dermoscopy (epiluminescence microscopy) of pigmented skin lesions. Current status and evolving trends. Dermatol Clin 1997;15:7995.

    • Search Google Scholar
    • Export Citation
  • 38.

    Nehal KS, Oliveria SA, Marghoob AA et al.. Use of and beliefs about dermoscopy in the management of patients with pigmented lesions: a survey of dermatology residency programmes in the United States. Melanoma Res 2002;12:601605.

    • Search Google Scholar
    • Export Citation
  • 39.

    Braun RP, Meier M, Pelloni F et al.. Teledermatoscopy in Switzerland: a preliminary evaluation. J Am Acad Dermatol 2000;42:770775.

  • 40.

    Piccolo D, Smolle J, Wolf IH et al.. Face-to-face diagnosis vs tele-diagnosis of pigmented skin tumors: a teledermoscopic study. Arch Dermatol 1999;135:14671471.

    • Search Google Scholar
    • Export Citation
  • 41.

    Nehal KS, Oliveria SA, Marghoob AA et al.. Use of and beliefs about baseline photography in the management of patients with pigmented lesions: a survey of dermatology residency programmes in the United States. Melanoma Res 2002;12:161167.

    • Search Google Scholar
    • Export Citation
  • 42.

    Morton DL, Cochran AJ, Thompson JF et al.. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302311.

    • Search Google Scholar
    • Export Citation
  • 43.

    American Society for Dermatologic Surgery. 2005 Procedure Survey: dermasurgery trends and statistics. Available at: http://www.asds-net.org/Media/Articles/ASDS2005StatsReport.pdf. Accessed May 20, 2006.

    • Search Google Scholar
    • Export Citation
  • 44.

    MacKie RM, Bray CA, Hole DJ. Observational study of type of surgical training and outcome of definitive surgery for primary malignant melanoma. BMJ 2002;325:12761277.

    • Search Google Scholar
    • Export Citation
  • 45.

    Dummer R, Panizzon R, Bloch PH, Burg G. Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology 2005;210:3944.

    • Search Google Scholar
    • Export Citation
  • 46.

    Sober AJ, Chuang TY, Duvic M et al.. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579586.

  • 47.

    Stante M, De Giorgi V, Carli P. Can dermopscopy improve the poor reliability of clinical approach in the diagnosis of lentigo maligna of the face? Br J Dermatol 2005;153:1084.

    • Search Google Scholar
    • Export Citation
  • 48.

    Kelley LC, Starkus L. Immunohistochemical staining of lentigo maligna during Mohs micrographic surgery using MART-1. J Am Acad Dermatol 2002;46:7884.

    • Search Google Scholar
    • Export Citation
  • 49.

    Bricca GM, Brodland DG, Ren D, Zitelli JA. Cutaneous head and neck melanoma treated with Mohs micrographic surgery. J Am Acad Dermatol 2005;52:92100.

    • Search Google Scholar
    • Export Citation
  • 50.

    Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003;149(suppl 66):58.

  • 51.

    Urosevic M, Maier T, Benninghoff B et al.. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 2003;139:13251332.

    • Search Google Scholar
    • Export Citation
  • 52.

    Suzuki H, Wang B, Shivji GM et al.. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000;114:135141.

    • Search Google Scholar
    • Export Citation
  • 53.

    Wolf IH, Cerroni L, Kodama K, Kerl H. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol 2005;141:510514.

    • Search Google Scholar
    • Export Citation
  • 54.

    Ray CM, Kluk M, Grin CM, Grant-Kels JM. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol 2005;44:428434.

    • Search Google Scholar
    • Export Citation
  • 55.

    Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003;97:639643.

    • Search Google Scholar
    • Export Citation
  • 56.

    Ferrone CR, Ben Porat L, Panageas KS et al.. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:16471654.

    • Search Google Scholar
    • Export Citation
  • 57.

    Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. Br J Dermatol 2002;146:10421046.

    • Search Google Scholar
    • Export Citation
  • 58.

    Fader DJ, Wise CG, Normolle DP, Johnson TM. The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad Dermat 1998;38:742751.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 451 107 14
PDF Downloads 325 69 11
EPUB Downloads 0 0 0